Strategic Report Financial Review In 2013, our financial performance was defined by significant revenue decline associated with loss of exclusivity.
2013 was also a year of investment in business development, with acquisitions in our three core therapy areas.
Contents Our financial performance in 2013 was Core R&D expenditures were up only 74 Introduction defined by the significant revenue decline 1%, to$4.3 billion.
The Group was able 75 Business background and associated with the loss of exclusivity to contain R&D costs despite increased results overview for several products.
Seroquel IR alone business development activities in 2013.
76 Measuring performance declined by over $900 million in constant This was possible due to strong cost 77 Results of operations currency terms, and regional losses of control and flexibility in the reallocation summary analysis of year exclusivity for brands, including Atacand of resources.
to 31 December 2013 and Crestor, combined for a further Reported operating profit, at $3.7 billion, 79 Cash flow and liquidity negative impact of more than $1 billion.
was adversely impacted by an impairment 80 Financial position The changing product mix also impacted charge of $1.8 billion taken against Bydureon.
82 Capitalisation and shareholder on our gross margin percentage.
In March 2013, we announced the fourth return As detailed in the Our relationships section phase of our restructuring programme.
82 Future prospects from page 70, 2013 was a year of investment Transforming the way we work is crucial 82 Financial risk management in business development.
The acquisitions to delivering our strategy and we are 83 Critical accounting policies we have made have been in our three committed to dramatically simplifying our and estimates core therapy areas with the intention of organisation and processes, while creating 87 Sarbanes-Oxley Act Section strengthening our pipeline or helping us an innovative environment, including 404 gain access to cutting-edge science.
through co-location on a more focused Our 7% increase in Core SG&A costs footprint.
Further details on our restructuring at CER reflects our focus on investing in programme are provided in the Restructuring our growth platforms.
The excise fee section from page 16.
We continue to drive imposed by the enactment of US healthcare productivity improvements across the reform measures amounted to 2.7% of organisation, removing complexity and Core SG&A costs.
creating additional headroom to invest in growing our business and ensuring returns We generated an incremental $1.2 billion to our shareholders.
of revenue at CER for our key growth platforms: Brilinta, the diabetes franchise, Marc Dunoyer respiratory, Emerging Markets and Japan.
Chief Financial Officer 74 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information The purpose of this Financial Review is to The timings of new product launches, Dividends paid decreased to provide a balanced and comprehensive which can be influenced by national $3,461 million 2012: $3,665 million.
analysis of the financial performance of the regulators, and the risk that such new There were no share repurchases in business during 2013, the financial position products do not succeed as anticipated, the year 2012: $2,635 million, following as at the end of the year, and the main together with the rate of sales growth and the announcement in October 2012 business factors and trends which could costs following new product launches.
of the suspension of the Groups share affect the future financial performance of Currency fluctuations.
and reporting currency is the US dollar, Total restructuring costs associated but we have substantial exposures to with the global programme to reshape All growth rates in this Financial Review are other currencies, in particular the euro, the cost base of the business were expressed at CER unless noted otherwise.
Japanese yen, pound sterling and $1,421 million in 2013.
The fourth phase Business background and results Swedish krona.
of restructuring is focused on the overview Macro factors such as greater demand restructuring of R&D, into strategic The business background is covered in from an ageing population and increasing research and development centres in the Our marketplace section from page requirements of Emerging Markets.
the US, the UK and Sweden to improve 13, the Therapy Area Review from page pipeline productivity.
The programme Over the longer term, the success of our 48 and the Geographical Review from has been expanded to include additional R&D is crucial and we devote substantial page 214, and describes in detail the activities such as a transformation of the resources to this area.
The benefits of this developments in both our products and the IT organisation, the exit of R&D activities investment are expected to emerge over geographical regions in which we operate.
in Bangalore, India, and the exit from the long-term and there is considerable branded generics in certain Emerging As described earlier in this Annual Report, inherent uncertainty as to whether and Markets to further reduce costs and sales of our products are directly influenced when it will generate future products.
Total restructuring by medical need and are generally paid for The most significant features of our financial costs charged since the start of our by health insurance schemes or national results in 2013 are: restructuring programme in 2007 amount healthcare budgets.
Our operating results to $7,848 million.
can be affected by a number of factors Revenue was down 6% to $25,711 million other than the delivery of operating plans Reported: 8% due to competition from and normal competition, such as: generics.
The key growth platforms of Brilinta, The risk of competition from generics the diabetes franchise, respiratory, following loss of patent protection or Emerging Markets and Japan, delivered patent expiry of one of our products or an incremental $1.2 billion of revenue at an at risk launch by a competitor or CER in 2013.
This was more than offset the launch of a generic competitor in by the impact of patent expiries which the same class as one of our products, reduced revenue by $2.2 billion at CER.
with the potential adverse effects on Core operating profit was down 22% at sales volumes and prices.
For example, CER Reported: 25% to $8,390 million, in 2013, our performance was affected greater than the decline in our revenue by generic competition to Atacand, primarily due to the higher expenditures Crestor, Nexium and Seroquel IR.
Further associated with our key growth platforms details of patent expiries for our key and strengthened pipeline.
marketed products are included in the Reported operating profit was down 51% Patent expiries section on page 198. at CER Reported: 54% to $3,712 million, The adverse impact on pharmaceutical driven by impairment charges including prices as a result of the macroeconomic $1,758 million for Bydureon.
For instance, Core operating margin of 33% of revenue although there is no direct governmental was down 6.9 percentage points at control on prices in the US, action from CER Reported: 7.3 percentage points.
federal and individual state programmes Reported operating margin was 14.4% and health insurance bodies is leading to of revenue.
downward pressures on realised prices.
Core EPS decreased by 23% Reported: In other parts of the world, there are a 26% to $5.05.
Reported EPS was down variety of price and volume control 55% Reported: 59% to $2.04.
mechanisms and retrospective rebates based on sales levels that are imposed by governments.
AstraZeneca Annual Report and Form 20-F Information 2013 75 Strategic Report | Financial Review Measuring performance The following measures are referred to Constant exchange rate CER growth As shown in the 2013 Reconciliation in this Financial Review when reporting rates.
These are also non-GAAP of Reported results to Core results table on our performance both in absolute measures.
These measures remove on the page opposite, our reconciliation terms, but more often in comparison the effects of currency movements of Reported financial information to Core to earlier years: by retranslating the current years financial measures includes a breakdown performance at previous years exchange of the items for which our Reported Reported performance.
Reported rates and adjusting for other exchange financial information is adjusted and a performance takes into account all the effects, including hedging.
further breakdown by specific line item as factors including those which we cannot A reconciliation of the Reported results such items are reflected in our Reported influence, principally currency exchange adjusted for the impact of currency income statement.
This illustrates the rates that have affected the results of movements is provided in the 2013 significant items that are excluded from our business, as reflected in our Group Reported operating profit table on the Core financial measures and their impact Financial Statements prepared in page opposite.
on our Reported financial information, accordance with IFRSs as adopted Gross and operating profit margin both as a whole and in respect of specific by the EU and as issued by the IASB.
These measures set out line items.
These are the progression of key performance non-GAAP measures because, unlike Management presents these results margins and illustrate the overall quality Reported performance, they cannot externally to meet investors requirements of the business.
be derived directly from the information for transparency and clarity.
Core financial Prescription volumes and trends for in the Groups Financial Statements.
measures are also used internally in the key products.
These measures can These measures are adjusted to exclude management of our business performance, represent the real business growth certain significant items, such as: in our budgeting process and when and the progress of individual products amortisation and impairment of determining compensation.
better and more immediately than intangibles, including impairment Core financial measures are non-GAAP invoiced sales.
reversals but excluding any charges measures.
All items for which Core financial Net funds debt.
This represents our relating to IT assets measures are adjusted are included in our cash and cash equivalents, current charges and provisions related to Reported financial information as they investments and derivative financial our global restructuring programmes represent actual costs of our business in instruments less interest-bearing loans this will include such charges that the periods presented.
As a result, Core and borrowings.
relate to the impact of our global financial measures merely allow investors restructuring programmes on our CER measures allow us to focus on the to differentiate between different kinds of capitalised IT assets changes in sales and expenses driven costs and they should not be used in other specified items, principally by volume, prices and cost levels relative isolation.
You should also refer to our comprising legal settlements and to the prior period.
Sales and cost growth Reported financial information in the 2013 acquisition-related costs which include expressed in CER allows management Reported operating profit table on the page fair value adjustments and the imputed to understand the true local movement opposite, our reconciliation of Core financial finance charge relating to contingent in sales and costs, in order to compare measures to Reported financial information consideration.
recent trends and relative return on in the Reconciliation of Reported results investment.
CER growth rates can be used to Core results table on the page opposite, In determining the adjustments to to analyse sales in a number of ways but, and to the Results of operations summary arrive at the Core result, we use a set most often, we consider CER growth by analysis of year to 31 December 2012 of established principles relating to products and groups of products, and by section from page 222 for our discussion the nature and materiality of individual countries and regions.
CER sales growth of comparative Reported growth measures items or groups of items, excluding, can be further analysed into the impact of that reflect all factors that affect our for example, events which i are sales volumes and selling price.
Our determination of non-GAAP outside the normal course of business, CER cost growth helps us to focus on the measures, and our presentation of them ii are incurred in a pattern that is real local change in costs so that we can within this financial information, may differ unrelated to the trends in the manage the cost base effectively.
from similarly titled non-GAAP measures underlying financial performance We believe that disclosing Core financial of other companies.
of our ongoing business, or iii are and growth measures, in addition to our related to major acquisitions, to ensure The SET retains strategic management Reported financial information, enhances that investors ability to evaluate of the costs excluded from Reported investors ability to evaluate and analyse and analyse the underlying financial financial information in arriving at Core the underlying financial performance of performance of our ongoing business financial measures, tracking their impact is enhanced.
See the 2013 our ongoing business and the related key on Reported operating profit and EPS, with Reconciliation of Reported results business drivers.
The adjustments made operational management being delegated to Core results table on the page to our Reported financial information in on a case-by-case basis to ensure clear opposite for a reconciliation of order to show Core financial measures accountability and consistency for each Reported to Core performance.
illustrate clearly, and on a year-on-year or cost category.
As detailed in our 2012 Annual Report, period-by-period basis, the impact upon we revised our definition of Core our performance caused by factors such performance measures in 2013. as changes in sales and expenses driven Further details of the restatement of by volume, prices and cost levels relative prior year comparative values under to such prior years or periods.
our new Core measure definition are included in the Financials Prior year section on page 222.
76 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information Results of operations summary analysis of year to 31 December 2013 2013 Reported operating profit 2013 2012 Percentage of sales 2013 compared with 2012 Growth due to Reported CER exchange Reported Reported CER growth Reported growth effects Reported 2013 2012 growth % $m $m $m $m % % % Revenue 25,711 1,701 561 27,973 6 8 Cost of sales 5,261 9 123 5,393 20.5 19.3 2 Gross profit 20,450 1,692 438 22,580 79.5 80.7 7 9 Distribution costs 306 10 4 320 1.2 1.1 3 4 Research and development 4,821 411 11 5,243 18.7 18.8 8 8 Selling, general and administrative costs 12,206 2,508 141 9,839 47.5 35.2 25 24 Other operating income and expense 595 379 4 970 2.3 3.5 39 39 Operating profit 3,712 4,158 278 8,148 14.4 29.1 51 54 Net finance expense 445 502 Profit before tax 3,267 7,646 Taxation 696 1,376 Profit for the period 2,571 6,270 Basic earnings per share $ 2.04 4.95 Restated on the adoption of IAS 19 2011, as detailed in the Group Accounting Policies section on page 136.
2013 Reconciliation of Reported results to Core results Core 2013 compared with 2012 Net Legal Actual 2013 Restructuring Intangible intangible provisions 2013 CER growth Reported costs amortisation impairments and other Core growth % $m $m $m $m $m $m % Gross profit 20,450 126 502 21,078 7 9 Gross margin % 79.5% 82.0% Distribution costs 306 306 3 4 Research and development 4,821 490 30 50 18 4,269 1 1 Selling, general and administrative costs 12,206 805 902 1,662 28 8,865 7 6 Other operating income and expense 595 157 752 30 30 Operating profit 3,712 1,421 1,591 1,712 46 8,390 22 25 Operating margin % 14.4% 32.6% Taxation 696 302 256 364 7 1,611 Basic earnings per share $ 2.04 0.90 1.06 1.08 0.03 5.05 Each of the measures in the Core column in the above table are non-GAAP measures.
Revenue for the year was down 6% on Core gross margin was 82.0%, 0.5 diabetes alliance with BMS on Amylin a CER basis and 8% on a Reported basis.
percentage points lower than last year at products entered into in 2012.
The excise The revenue decline was driven by a loss CER Reported: 0.4 percentage points fee imposed by the enactment of US of exclusivity on brands including Atacand, driven by changes in our product mix to healthcare reform measures amounted Crestor, Nexium and Seroquel IR, which lower margin products when compared to 2.7% 2012: 2.8% of Core SG&A costs reduced revenue by $2.2 billion at CER.
Our key growth platforms of Brilinta, the Core R&D expense for the year was up Core other income for the year was diabetes franchise which benefited from 1% at CER and Reported, as a result of down 30% at CER and Reported, with a full year of Amylin-related product sales, absorbing higher costs from business 2012 benefiting from the sale of OTC respiratory, Emerging Markets and Japan development projects as well as investment rights for Nexium.
delivered an incremental $1.2 billion of in the growing number of late-stage trials.
Core operating profit for the year was down Expenditures in Core number of SG&A 22% on a CER basis Reported: 25% to Revenue in the US was down 9% on a CER costs were 7% higher than last year at CER $8,390 million.
Core operating margin was basis Reported: 9% with revenue in the Reported: 6%, as a result of increased 32.6% of revenue, down 6.9 percentage Rest of World down 4% at CER Reported: levels of expenditure in support of our points at CER Reported: 7.3 percentage 7%.
Emerging Markets sales increased by growth platforms of Brilinta, the diabetes points.
The decline in Core operating profit 8% at CER Reported: 6%.
Further details franchise and Emerging Markets during was greater than the decline in revenue of our sales performance are contained in the year.
SG&A costs also reflect a full year primarily due to expenditure associated the Geographical Review from page 214. of costs associated with our expanded with the Groups key growth platforms and strengthened pipeline.
AstraZeneca Annual Report and Form 20-F Information 2013 77 Strategic Report | Financial Review Core EPS was $5.05, down 23% compared Legal provisions and other adjustments The Reported tax rate for the year was with last year at CER Reported: 26%, and of $46 million income 2012: $133 million 21.3% compared with 18.0% for 2012. broadly in line with the decline in Core charges including an $18 million The Reported tax rate for the year ended operating profit.
adjustment to the fair value of contingent 31 December 2012 benefited from a consideration payable arising on our $230 million adjustment to deferred tax Pre-tax adjustments to arrive at Core business combinations completed in balances following substantive enactment amounted to $4,678 million in 2013 2013, as detailed in Notes 16 and 22 to of a reduction in the Swedish corporation 2012: $3,011 million.
Excluded from the Financial Statements on page 158 tax rate from 26.3% to 22.0%, and a Core results were: and from page 166.
$240 million adjustment in respect of Restructuring costs totalling $1,421 million prior periods following the settlement of Reported operating profit for the year 2012: $1,558 million, incurred as the a transfer pricing matter.
Excluding these was down 51% at CER Reported: 54% to Group commenced the fourth phase of benefits, the Reported tax rate for 2012 $3,712 million: Reported EPS was down restructuring announced in March 2013. was 24.1%.
Further details relating to 55% on a CER basis Reported: 59% to Amortisation totalling $1,591 million movements in our taxation balances $2.04.
The larger declines compared with 2012: $1,134 million relating to intangible are included in Note 4 to the Financial the respective Core financial measures assets, except IT-related amortisation Statements from page 143. are mainly the result of the $1,758 million charges.
The increase was driven by impairment of Bydureon, as well as the Total comprehensive income for a full year of amortisation arising from full year amortisation related to the Merck 2013 decreased by $3,947 million the amendment to the Merck exit Second Option.
This was driven by arrangements and the expansion of our the decrease in profit for the year of Net finance expense was $445 million diabetes alliance during 2012, as detailed $3,699million, and a decrease of 2012: $502 million.
Interest payable on in Note 9 to the Financial Statements $248million in other comprehensive defined benefit pension scheme liabilities from page 150. income which was principally due to fell by $14 million, and there were fair value Net intangible impairment charges of effects of movements in exchange rates gains of $5 million recorded on long-term $1,712 million 2012: $186 million, on our consolidated results.
bonds in 2013, versus $10 million losses in including $1,758 million against 2012.
Interest on long-term bonds for the Bydureon, following sales performance year was $16 million lower than 2012. below AstraZenecas commercial expectations at the time of entering into The Reported taxation charge of the expanded diabetes alliance in 2012, $696 million 2012: $1,376million, and $136 million following AstraZenecas consisted of a current tax charge decision not to proceed with regulatory of $1,398million 2012: $1,677million filings for fostamatinib.
Partially offsetting and a credit arising from movements these charges was the impairment on deferred tax of $702million reversal of $285 million following the 2012: $301million.
The current tax commencement of the first of several charge includes a prior period current Phase III clinical programmes for olaparib.
tax charge of $46 million 2012: credit The full historic carrying value of the asset of $79 million.
has been restored to our balance sheet.
Further details relating to intangible asset impairments are included in Note 9 to the Financial Statements from page 150.
78 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information Cash flow and liquidity 2013 All data in this section is on a Reported basis.
Summary cash flows 2013 2012 2011 $m $m $m Net debt funds brought forward at 1 January 1,369 2,849 3,653 Earnings before interest, tax, depreciation, amortisation and impairment EBITDA 8,295 10,666 15,345 Profit on disposal of Astra Tech 1,483 EBITDA before profit on disposal of Astra Tech 8,295 10,666 13,862 Movement in working capital and short-term provisions 166 706 897 Tax paid 844 2,043 3,999 Interest paid 475 545 548 Non-cash and other movements 258 424 597 Net cash available from operating activities 7,400 6,948 7,821 Purchase of intangibles net 1,281 3,947 458 Other capital expenditure net 673 473 737 Acquisitions of business operations 1,158 1,187 Net cash received on disposal of Astra Tech 1,772 Investments 3,112 5,607 577 Dividends 3,461 3,665 3,764 Net share proceeds repurchases 482 2,206 5,606 Distributions 2,979 5,871 9,370 Other movements 99 312 168 Net funds debt carried forward at 31 December 39 1,369 2,849 Net funds debt reconciliation 2013 2012 2011 $m $m $m Cash and cash equivalents 9,217 7,701 7,571 Short-term investments 796 823 4,248 Net derivative financial instruments 402 417 358 Cash, short-term investments and derivatives 10,415 8,941 12,177 Overdraft and short-term borrowings 992 879 221 Finance leases 102 84 Current instalments of loans 766 1,769 Loans due after one year 8,516 9,347 7,338 Loans and borrowings 10,376 10,310 9,328 Net funds debt 39 1,369 2,849 Cash generated from operating purchase of other intangible assets.
debt outstanding at 31 December 2013, activities was $7,400 million in the year The comparative period of 2012 included $1,788million is due within one year ended 31 December 2013, compared the cash outflows for the purchase of 2012:$901 million.
Lower tax and Ardea $1,187 million and intangible assets Net funds of $39 million have increased interest payments partially offset the lower associated with our collaboration with by $1,408 million during the year as a result operating profit in 2013, after adjusting for BMS on Amylin $3,358 million.
of the net cash inflow as described above.
impairments and non-cash costs, while Net cash distributions to shareholders working capital movements and a one-off Off-balance sheet transactions and were $2,979 million, through dividends of pension fund contribution drove higher commitments $3,461million partially offset by proceeds outflows in the prior year.
We have no off-balance sheet from the issue of shares of $482 million.
arrangements and our derivative activities Investment cash outflows of $3,112 million At 31 December 2013, outstanding are non-speculative.
The table below sets 2012: $5,607 million included $1,158million gross debt interest-bearing loans out our minimum contractual obligations on completion of the acquisitions of Pearl and borrowings was $10,376 million at the year end.
Therapeutics, Omthera, Amplimmune and 2012: $10,310 million.
Of the gross Spirogen, and $1,316 million for the Payments due by period Less than Over 2013 2012 1 year 1-3 years 3-5 years 5 years Total Total $m $m $m $m $m $m 1 Bank loans and other borrowings 2,210 1,875 2,433 10,497 17,015 17,316 Finance leases 34 64 21 119 101 Operating leases 92 150 98 110 450 434 Contracted capital expenditure 481 481 245 Total 2,817 2,089 2,552 10,607 18,065 18,096 1 Bank loans and other borrowings include interest charges payable in the period, as detailed in Note 23 to the Financial Statements on page 169.
AstraZeneca Annual Report and Form 20-F Information 2013 79 Strategic Report | Financial Review Financial position 2013 All data in this section is on a Reported basis.
In 2013, net assets decreased by $693million enrolment of the first patient in the first of $681 million of cash payments.
The decrease in net several Phase III clinical programmes for within the $771 million of charges for assets is broadly as a result of the Group olaparib, an impairment provision previously the year is $652 million for our global profit of $2,571 million being offset by having being taken against this compound restructuring initiative and $23 million in dividends of $3,499 million.
in 2011. respect of legal charges.
Cash payments include $532 million for our global Property, plant and equipment Further details of our additions to intangible restructuring programme.
Further details Property, plant and equipment decreased assets, and impairments recorded, are of the charges made against provisions by $271 million to $5,818 million.
Additions included in Note 9 to the Financial are contained in Notes 17 and 25 to the of $816 million 2012: $772 million were Statements from page 150.
Financial Statements on page 158, and offset by depreciation of $906 million Receivables, payables and provisions 176 to 183, respectively.
2012: $1,023 million, impairments of Trade receivables decreased by $101 million 2012: $nil and disposals Tax payable and receivable $182million to $5,514 million in line of $82 million 2012: $224 million.
Net income tax payable has increased by with lower revenues in 2013.
$523 million to $2,582 million, principally Goodwill and intangible assets Prepayments and accrued income due to cash tax timing differences and an The Groups goodwill of $9,981 million increased by $1,988 million driven, increase in accruals for tax contingencies.
2012: $9,898 million principally arose on principally, by an increase in prepayments The tax receivable balance of $494 million the acquisition of MedImmune in 2007 and following the modification of the royalty comprises tax owing to AstraZeneca the restructuring of our US joint venture structure under our global licence from certain governments expected to be with Merck in 1998.
Goodwill of $77 million agreement for Crestor, which now includes received on settlements of transfer pricing arising on our acquisitions of Pearl fixed minimum and maximum annual audits and disputes see Note 25 to the Therapeutics and Amplimmune, as detailed royalty payments to Shionogi.
These Financial Statements from page 176 and in Note 22 to the Financial Statements from future royalties have been recognised cash tax timing differences.
Net deferred page 166, was capitalised in 2013. within payables and as a prepayment.
tax liabilities increased by $157 million Intangible assets amounted to $16,047 Prepayments also increased due to in the year.
million at 31 December 2013 2012: payments made to Moderna Therapeutics Retirement benefit obligations $16,448million.
Intangible asset additions and Immunocore during the year on new Net retirement benefit obligations were $3,217 million in 2013 2012: research collaborations.
Employer $6,916million, including product rights Trade and other payables increased by contributions to the pension scheme of acquired in our acquisitions of Pearl $2,492 million in 2013 to $12,714 million, $369 million were offset by current and Therapeutics $985 million, Omthera with increases in other payables of past service cost charges of $204 million, $526million, Amplimmune $534 million $2,277 million due to the recognition of net financing costs of $79 million and and Spirogen $371 million.
Amortisation future royalty payments on Crestor, as exchange movements.
in the year was $1,779 million 2012: detailed above, and contingent consideration $1,296million.
Impairment charges in the Approximately 97% of the Groups of $532 million recognised on the acquisitions year amounted to $2,082 million 2012: obligations are concentrated in the UK, of Pearl Therapeutics $149 million, $199 million including a $1,758 million the US, Sweden and Germany.
In recent Omthera $62 million, Amplimmune charge on our diabetes product Bydureon years, the Group has undertaken several $153 million and Spirogen $168 million.
and a $136 million impairment charge initiatives to reduce its net pension following our decision not to proceed with The increase in provisions of $45 million obligation exposure.
For the UK defined regulatory filings for fostamatinib.
These in 2013 includes $771 million of additional benefit pension scheme, which is impairment charges were partially offset by charges recorded in the year, offset by AstraZenecas largest defined benefit a $285 million impairment reversal following 80 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information scheme, these initiatives have included business acquisitions and disposals in the future development-related milestone agreeing funding principles for cash past three years are contained in Note 22 payments of up to $465 million, and contributions to be paid into the UK to the Financial Statements from page 166. potential future sales-related milestone pension scheme to target a level of assets Details of our significant externalisation payments, in addition to tiered royalty in excess of the current expected cost transactions are given below: payments on future sales of roxadustat of providing benefits, and, in 2010, in the low 20% range.
Additional In March 2013, AstraZeneca signed an amendments to the scheme to freeze development milestones will be payable exclusive agreement with Moderna pensionable pay at 30 June 2010 levels.
for any subsequent indications which Therapeutics to discover, develop and In addition to the cash contributions the companies choose to pursue.
commercialise pioneering medicines to be paid into the UK pension scheme, AstraZeneca will be responsible for based on messenger RNA Therapeutics AstraZeneca makes contributions to an the US commercialisation of roxadustat, for the treatment of serious cardiovascular, escrow account which is held outside the with FibroGen undertaking specified metabolic and renal diseases as well pension scheme.
The escrow account promotional activities in the ESRD as cancer.
Under the terms of the assets are payable to the fund in agreed segment in this market.
The companies agreement, AstraZeneca made an circumstances, for example, in the event of will also co-commercialise roxadustat in upfront payment of $240 million.
AstraZeneca and the pension fund trustee China where FibroGen will be responsible AstraZeneca will have exclusive access agreeing a change to the current long-term for clinical trials, regulatory matters, to select any target of its choice in investment strategy.
manufacturing and medical affairs, and cardiometabolic and renal diseases, AstraZeneca will oversee promotional Further details of the Groups pension as well as selected targets in oncology, activities and commercial distribution.
schemes are included in Note 18 to the over a period of up to five years for In April 2012, AstraZeneca announced Financial Statements from page 159. subsequent development of messenger an agreement to jointly develop and RNA Therapeutics.
In addition, Moderna Commitments and contingencies commercialise five monoclonal Therapeutics is entitled to an additional The Group has commitments and antibodies from Amgens clinical $180 million for the achievement of contingencies which are accounted for in inflammation portfolio: AMG 139, AMG three technical milestones.
Through accordance with the accounting policies 157, AMG 181, AMG 557 and brodalumab this agreement, AstraZeneca has the described in the Financial Statements in AMG 827.
Under the terms of the option to select up to 40 drug products the Group Accounting Policies section agreement, AstraZeneca made a for clinical development and Moderna from page 136.
The Group also has $50 million upfront payment and the Therapeutics will be entitled to taxation contingencies.
These are companies share both costs and profits.
development and commercial milestone described in the Taxation section in the Approximately 65% of costs for the payments as well as royalties on drug Critical accounting policies and estimates 2012 to 2014 period are funded by sales ranging from high single digits section on page 87 and in Note 25 to the AstraZeneca.
Thereafter, the companies to low double digits for each product.
Financial Statements from page 176. will split costs equally.
In addition, AstraZeneca will lead the pre-clinical, AstraZeneca will make development Research and development clinical development and commercialisation milestone payments up to a maximum collaboration payments of therapeutics resulting from the of $30 million up to launch.
On Details of future potential R&D collaboration agreement and Moderna Therapeutics commercialisation, Amgen will retain a payments are also included in Note 25 will be responsible for designing and low-single-digit royalty for brodalumab to the Financial Statements from page 176. manufacturing the messenger RNA and a mid-single-digit royalty for the rest As detailed in Note 25 to the Financial Therapeutics against selected targets.
of the portfolio after which the companies Statements, payments to our collaboration In July 2013, AstraZeneca entered into will share profits equally.
partners may not become payable due to astrategic collaboration with FibroGen In January 2007, AstraZeneca signed the inherent uncertainty in achieving the todevelop and commercialise roxadustat anexclusive co-development and development and revenue milestones linked FG-4592, a first-in-class oral compound co-promotion agreement with BMS for to the future payments.
As part of our in late-stage development for the the development and commercialisation overall externalisation strategy, we may treatment of anaemia associated with of Onglyza, a DPP-IV and Farxiga Forxiga, enter into further collaboration projects chronic kidney disease CKD and a selective sodium-glucose coin the future that may include milestone end-stage renal disease ESRD.
This transporter 2 SGLT-2 inhibitor, both payments and, therefore, as certain broad collaboration focuses on the US, forthe treatment of Type 2 diabetes.
In milestone payments fail to crystallise due to, China and all major markets excluding August 2012, AstraZeneca expanded its for example, development not proceeding, Japan, Europe, the CIS, the Middle East diabetes alliance with BMS to incorporate they may be replaced by potential and South Africa, which are covered the development and marketing of payments under new collaborations.
by an existing agreement between Amylins portfolio of diabetes products.
The , divestments and capital The portfolio of collaboration products FibroGen joint effort will be focused on expenditure in Amylin includes Byetta exenatide the development of roxadustat to treat The Group has completed over 150 major injection and Bydureon exenatide anaemia in CKD and ESRD, and may be business development transactions over extended-release for injectable extended to other anaemia indications.
the past three years, five of which were suspension exenatide 2mg powder AstraZeneca and FibroGen plan to accounted for as business acquisitions and solvent for prolonged release undertake an extensive roxadustat Phase under IFRS 3 Business Combinations, suspension for injection, Symlin III development programme for the US, being the acquisitions of Pearl Therapeutics, pramlinitide acetate injection, and and to initiate Phase III trials in China, with Omthera, Amplimmune and Spirogen in metreleptin, a leptin analogue.
AstraZeneca anticipated regulatory filings in China in 2013, and Ardea in 2012, and all others expanded the alliance for a total 2015 and in the US in 2017.
AstraZeneca being in-licences, strategic alliances and consideration of $3.7billion.
In December will pay FibroGen committed upfront and collaborations.
Further details of our 2013, AstraZeneca announced an subsequent non-contingent payments agreement under which AstraZeneca totalling $350 million, as well as potential AstraZeneca Annual Report and Form 20-F Information 2013 81 Strategic Report | Financial Review Capitalisation and shareholder return Dividend for 2013 $ Pence SEK Payment date First interim dividend 0.90 59.2 5.92 16 September 2013 Second interim dividend 1.90 116.8 12.41 24 March 2014 Total 2.80 176.0 18.33 Summary of shareholder distributions Shares Dividend per Dividend Shareholder repurchased Cost share cost distributions million $m $ $m $m 2000 9.4 352 0.70 1,236 1,588 2001 23.5 1,080 0.70 1,225 2,305 2002 28.3 1,190 0.70 1,206 2,396 2003 27.2 1,154 0.795 1,350 2,504 2004 50.1 2,212 0.94 1,555 3,767 2005 67.7 3,001 1.30 2,068 5,069 2006 72.2 4,147 1.72 2,649 6,796 2007 79.9 4,170 1.87 2,740 6,910 2008 13.6 610 2.05 2,971 3,581 2009 2.30 3,339 3,339 2010 53.7 2,604 2.55 3,604 6,208 2011 127.4 6,015 2.80 3,653 9,668 2012 57.8 2,635 2.80 3,496 6,131 1 2013 2.80 3,516 3,516 Total 610.8 29,170 24.025 34,608 63,778 1 Total dividend cost estimated based upon number of shares in issue at 31 December 2013. acquired the entirety of BMSs interests payments and the resources used for This dividend is consistent with the inthe companies diabetes alliance for commercialisation activities for example, progressive dividend policy, by which the an initial consideration of $2.7 billion the number of staff.
Qualitative factors we Board intends to maintain or grow the on completion and up to $1.4 billion in consider include, without limitation, new dividend each year.
regulatory, launch and sales-related market developments, new territories, new The Board regularly reviews its distribution payments.
AstraZeneca has also agreed areas of research and strategic implications.
policy and its overall financial strategy to to pay various sales-related royalty In aggregate, payments capitalised under continue to strike a balance between the payments up until 2025.
In addition, the Groups externalisation arrangements, interests of the business, our financial AstraZeneca may make payments up other than those detailed above, amounted creditors and our shareholders.
Having to $225 million when certain assets to $301 million in 2013, $156 million in regard for business investment, funding are subsequently transferred.
The Group the progressive dividend policy and business combination completed on recognised other income in respect of meeting our debt service obligations, the 1 February 2014, and provides other externalisation arrangements totalling Board currently believes it is appropriate AstraZeneca with 100% ownership $20 million in 2013, $255 million in 2012 to continue the suspension of the share of the intellectual property and global including $250 million of income from an repurchase programme which was rights for the development, manufacture agreement with Pfizer for OTC rights for announced in October 2012. and commercialisation of the diabetes Nexium, and $18 million in 2011.
Further details of this business We believe challenging market conditions combination are included in Note 28 to Capitalisation will persist in 2014, including continued the Financial Statements from page 184.
The total number of shares in issue at government interventions on price.
The Group determines the above business revenue impact from the loss of exclusivity 10.4million Ordinary Shares were issued development transactions to be significant will also continue to affect our performance in consideration of share option exercises using a range of factors.
We look at the including the anticipated Nexium US first for a total of $451 million.
There were no specific circumstances of the individual generic launch in May 2014. share repurchases in 2013.
Shareholders externalisation arrangement and apply equity decreased by $507 million to several quantitative and qualitative criteria.
Financial risk management $23,224million at the year end.
NonBecause we consider business development Financial risk management policies controlling interests decreased to transactions to be an extension of our Insurance $29million 2012: $215 million, mainly R&D strategy, the expected total value Our risk management processes are driven by changes in non-controlling of development payments under the described in the Managing risk section from interests shareholdings in Japan.
transaction and its proportion of our annual page 199.
These processes enable us to R&D spend, both of which are proxies for Dividend and share repurchases identify risks that can be partly or entirely overall R&D effort and cost, are important The Board has recommended a second mitigated through the use of insurance.
elements of the significance determination.
interim dividend of $1.90 116.8 pence, We negotiate best available premium rates Other quantitative criteria we apply include, 12.41 SEK to be paid on 24 March 2014. with insurance providers on the basis of our without limitation, expected levels of future This brings the full year dividend to $2.80 extensive risk management procedures.
sales, the possible value of milestone 176.0 pence, 18.33 SEK.
In the current insurance market, the level 82 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information of cover is decreasing while premium rates Sensitivity analysis of the Groups Chargebacks, where we enter into are increasing.
Rather than simply paying exposure to exchange rate and interest arrangements under which certain higher premiums for lower cover, we focus rate movements is also detailed in Note 23 parties, typically hospitals, the our insurance resources on the most critical to the Financial Statements from page 169.
Department of Veterans Affairs, Public areas, or where there is a legal requirement, Health Service Covered Entities and the Critical accounting policies and and where we can get best value for Department of Defense, are able to buy estimates money.
Risks to which we pay particular products from wholesalers at the lower Our Financial Statements are prepared attention include business interruption, prices we have contracted with them.
in accordance with IFRSs as adopted by Directors and Officers liability, and The chargeback is the difference the EU adopted IFRS and as issued by property damage.
Insurance for product between the price we invoice to the the IASB, and the accounting policies liability has not been available on wholesaler and the contracted price employed are set out in the Group commercially acceptable terms for several charged by the wholesaler.
Chargebacks Accounting Policies section in the Financial years and the Group has not purchased in are paid directly to the wholesalers.
In applying the market product liability insurance since Regulatory, including Medicaid and other these policies, we make estimates and February 2006. federal and state programmes, where we assumptions that affect the reported pay rebates based on the specific terms Taxation amounts of assets and liabilities and of agreements with the US Department Tax risk management forms an integrated disclosure of contingent assets and of Health and Human Services and with part of the Groups risk management liabilities.
The actual outcome could differ individual states, which include product processes.
Our tax strategy is to manage from those estimates.
Some of these usage and information on best prices tax risks and tax costs in a manner policies require a high level of judgement and average market prices benchmarks.
consistent with shareholders best because the areas are especially subjective Contractual, under which entities such as long-term interests, taking into account or complex.
We believe that the most third party managed-care organisations, both economic and reputational factors.
critical accounting policies and significant long-term care facilities and group We draw a distinction between tax planning areas of judgement and estimation are in: purchasing organisations are entitled using artificial structures and optimising tax revenue recognition to rebates depending on specified treatment of business transactions, and we research and development performance provisions, which vary engage only in the latter.
impairment testing of goodwill and from contract to contract.
intangible assets Treasury The effects of these deductions on our litigation The principal financial risks to which the US pharmaceuticals revenue and the post-retirement benefits Group is exposed are those arising from movements on US pharmaceuticals taxation.
liquidity, interest rate, foreign currency revenue provisions are set out overleaf.
The Group has a centralised Revenue recognition Accrual assumptions are built up on a treasury function to manage these risks Revenue is recorded at the invoiced product-by-product and customer-byin accordance with Board-approved amount excluding inter-company sales customer basis, taking into account policies.
Specifically, liquidity risk is and value-added taxes less movements specific contract provisions coupled with managed through maintaining access in estimated accruals for rebates and to a number of sources of funding to expected performance, and are then chargebacks given to managed-care and meet anticipated funding requirements, aggregated into a weighted average rebate other customers and product returns a including committed bank facilities and accrual rate for each of our products.
particular feature in the US.
The impact in cash resources.
Interest rate risk is Accrual rates are reviewed and adjusted the rest of the world is not significant.
It is managed through maintaining a debt on a monthly basis.
There may be further the Groups policy to offer a credit note for portfolio that is weighted towards fixed adjustments when actual rebates are all returns and to destroy all returned stock rates of interest.
Accordingly, the Groups invoiced based on utilisation information in all markets.
Cash discounts for prompt net interest charge is not significantly submitted to us in the case of contractual payment are also deducted from sales.
affected by movements in floating rates rebates and claims invoices are received Revenue is recognised at the point of of interest.
We do not currently hedge in the case of regulatory rebates and delivery, which is usually when title passes the impact on earnings and cash flow chargebacks.
We believe that we have to the customer, either on shipment or of changes in exchange rates, with the made reasonable estimates for future on receipt of goods by the customer exception of the currency exposure that rebates using a similar methodology to that depending on local trading terms.
Income arises between the booking and settlement of previous years.
Inevitably, however, such from royalties and from disposals of IP, dates on non-local currency purchases estimates involve judgements on aggregate brands and product lines is included in and sales by subsidiaries and the external future sales levels, segment mix and the other operating income.
Credit risk is managed through customers contractual performance.
setting and monitoring credit limits Rebates, chargebacks and returns Managed-care and group purchasing appropriate for the assessed risk of in the US organisation rebate charges increased by the counterparty.
When invoicing sales in the US, we estimate $1,321 million in 2013 2012: $160 million: the rebates and chargebacks that we Our capital and risk management 2011: $682 million mainly due to the expect to pay.
These rebates typically objectives and policies are described in higher contracted rates in the commercial arise from sales contracts with third party further detail in Note 23 to the Financial and Medicare Part D segments due to managed-care organisations, hospitals, Statements from page 169 and in the Risk pricing pressures and the impact of 2013 long-term care facilities, group purchasing section from page 199. price increases.
organisations and various federal or state programmes Medicaid best price Cash discounts are offered to customers contracts, supplemental rebates etc.
Accruals They can be classified as follows: are calculated based on historical experience and are adjusted to reflect actual experience.
AstraZeneca Annual Report and Form 20-F Information 2013 83 Strategic Report | Financial Review Gross to net sales US Pharmaceuticals 2013 2012 2011 $m $m $m Gross sales 21,345 20,747 23,613 Chargebacks 2,449 2,261 1,958 Regulatory US government and state programmes 1,435 1,426 2,293 Contractual Managed-care and group purchasing organisation rebates 6,918 5,597 5,437 Cash and other discounts 399 401 452 Customer returns 112 182 72 Other 341 273 276 Net sales 9,691 10,607 13,125 Movement in provisions US Pharmaceuticals Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2013 current year prior years payments 2013 $m $m $m $m $m Chargebacks 313 2,439 10 2,407 355 Regulatory US government and state programmes 825 1,447 12 1,476 784 Contractual Managed-care and group purchasing organisation rebates 1,348 6,951 33 6,552 1,714 Cash and other discounts 33 399 400 32 Customer returns 211 99 13 101 222 Other 45 341 312 74 Total 2,775 11,676 22 11,248 3,181 Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2012 current year prior years payments 2012 $m $m $m $m $m Chargebacks 395 2,296 35 2,343 313 Regulatory US government and state programmes 1,290 1,585 159 1,891 825 Contractual Managed-care and group purchasing organisation rebates 1,600 5,578 19 5,849 1,348 Cash and other discounts 41 401 409 33 Customer returns 121 117 65 92 211 Other 80 273 308 45 Total 3,527 10,250 110 10,892 2,775 Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2011 current year prior years payments 2011 $m $m $m $m $m Chargebacks 523 2,012 54 2,086 395 Regulatory US government and state programmes 1,122 2,364 71 2,125 1,290 Contractual Managed-care and group purchasing organisation rebates 1,194 5,452 15 5,031 1,600 Cash and other discounts 41 452 452 41 Customer returns 133 75 3 84 121 Other 64 276 260 80 Total 3,077 10,631 143 10,038 3,527 84 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information Industry practice in the US allows We have distribution service agreements Research and development wholesalers and pharmacies to return with major wholesaler buyers which serve Our business is underpinned by our unused stocks within six months of, and to reduce the speculative purchasing marketed products and development up to 12 months after, shelf-life expiry.
behaviour of the wholesalers and reduce portfolio.
The R&D expenditure on internal The customer is credited for the returned short-term fluctuations in the level of activities to generate these products product by the issuance of a credit note.
We do not offer any is generally charged to profit in the year Returned products are not exchanged for incentives to encourage wholesaler that it is incurred.
Purchases of IP and products from inventory and once a return speculative buying and attempt, where product rights to supplement our R&D claim has been determined to be valid possible, to restrict shipments to underlying portfolio are capitalised as intangible and a credit note has been issued to the demand when such speculation occurs.
Further details of this policy customer, the returned products are are included in the Group Accounting Sales of intangible assets destroyed.
At the point of sale in the US, Policies section of our Financial Statements A consequence of charging all internal R&D we estimate the quantity and value of from page 136.
Such intangible assets are expenditure to the income statement in the products which may ultimately be returned.
amortised from the launch of the underlying year in which it is incurred which is normal Our returns accruals in the US are based products and are tested for impairment practice in the pharmaceutical industry on actual experience.
Our estimate is both before and after launch.
This policy is that we own valuable intangible assets based on the preceding 12 months for is in line with practice adopted by major which are not recorded on the balance established products together with pharmaceutical companies.
We also own acquired intangible market-related information, such as assets which are included on the balance Impairment testing of goodwill and estimated stock levels at wholesalers and sheet.
As a consequence of regular reviews intangible assets competitor activity, which we receive via of product strategy, from time to time we We have significant investments in third party information services.
For newly sell such assets and generate income.
goodwill and intangible assets as a result of launched products, we use rates based Sales of product lines are often accompanied acquisitions of businesses and purchases on our experience with similar products by an agreement on our part to continue of assets, such as product development or a pre-determined percentage.
manufacturing the relevant product for a and marketing rights.
For products facing generic competition reasonable period often about two years Details of the estimates and assumptions such as Atacand and the Toprol-XL while the purchaser constructs its own we make in our annual impairment testing franchise in the US our experience is that manufacturing facilities.
The contracts of goodwill are included in Note 8 to we usually lose the ability to estimate the typically involve the receipt of an upfront the Financial Statements on page 149. levels of returns from wholesalers with the payment, which the contract attributes The Group, including acquisitions, is same degree of precision that we can for to the sale of the intangible assets, and considered a single cash-generating unit products still subject to patent protection.
ongoing receipts, which the contract for impairment purposes.
No impairment This is because we have limited or no attributes to the sale of the product we of goodwill was identified.
insight into a number of areas: the actual manufacture.
In cases where the timing of the generic launch for example, a transaction has two or more components, Impairment reviews have been carried generic manufacturer may or may not have we account for the delivered item for out on all intangible assets that are in produced adequate pre-launch inventory : example, the transfer of title to the development and not being amortised, all the pricing and marketing strategy of the intangible asset as a separate unit of major intangible assets acquired during the competitor: the take-up of the generic: and accounting and record revenue on delivery year and all intangible assets that have had in cases where a generic manufacturer has of that component, provided that we can indications of impairment during the year.
approval to launch only one dose size in a make a reasonable estimate of the fair value Sales forecasts and specific allocated market of several dose sizes the likely level of the undelivered component.
Where the costs which have both been subject to of switching from one dose to another.
fair market value of the undelivered appropriate senior management sign-off Under our accounting policy, revenue is component for example, a manufacturing are discounted using appropriate rates recognised only when the amount of the agreement exceeds the contracted based on AstraZenecas risk-adjusted, revenue can be measured reliably.
Our price for that component, we defer pre-tax weighted average cost of capital.
approach in meeting this condition for an appropriate element of the upfront Our weighted average cost of capital products facing generic competition will consideration and amortise this over the reflects factors such as our capital structure vary from product to product depending performance period.
However, where and our costs of debt and equity.
In on the specific circumstances.
the fair market value of the undelivered building to the range of rates used in our component is equal to or lower than the internal investment appraisal of future The closing adjustment in respect of contracted price for that component, we projects and capital investment decisions, prior years increased 2013 net US we adjust our weighted average cost treat the whole of the upfront amount as pharmaceuticals revenue by 0.2% 2012: of capital for other factors which reflect, being attributable to the delivered intangible increased revenue by 1.0%: 2011: increased without limitation, local matters such as assets and recognise that part of the revenue by 1.1%.
However, taking into risk on a case-by-case basis.
No element of account the adjustments affecting both the the contracted revenue related to the current and the prior year, 2012 revenue undelivered component is allocated to the was reduced by 0.8%, and 2011 revenue sale of the intangible asset.
This is because was reduced by 0.3%, by adjustments the contracted revenue relating to the between years.
undelivered component is contingent on future events such as sales and so cannot be anticipated.
AstraZeneca Annual Report and Form 20-F Information 2013 85 Strategic Report | Financial Review A significant portion of our investments In cases that have been settled or Although there can be no assurance in intangible assets and goodwill arose adjudicated, or where quantifiable fines regarding the outcome of legal from the restructuring of the joint venture and penalties have been assessed and proceedings, we do not currently expect with Merck in 1998, the acquisition of which are not subject to appeal or other them to have a material adverse effect MedImmune in 2007, and the payments similar forms of relief, or where a loss on our financial position, but they could to partially retire Mercks interests in is probable more than 50% assessed significantly affect our financial results our products in the US in 2008 and probability and we are able to make a in any particular period.
In addition, our recent business reasonable estimate of the loss, we indicate Post-retirement benefits combinations, as detailed in Note 22 to the loss absorbed or the amount of the We offer post-retirement benefit plans the Financial Statements from page 166, provision accrued.
which cover many of our employees around have added significant product, marketing Where it is considered that the Group is the world.
In keeping with local terms and and distribution intangible rights to our more likely than not to prevail, or in the rare conditions, most of these plans are defined intangible asset portfolio.
As detailed circumstances where the amount of the contribution in nature, where the resulting earlier in this section of the Annual Report, legal liability cannot be estimated reliably, income statement charge is fixed at a set we recorded an impairment charge of legal costs involved in defending the claim level or is a set percentage of employees $1,758 million against the intangible are charged to profit as they are incurred.
However, several plans, mainly in the asset relating to Bydureon in 2013.
We Where it is considered that the Group has UK which has by far the largest single also recorded an impairment reversal of a valid contract which provides the right scheme, the US and Sweden, are defined $285 million on our intangible asset for to reimbursement from insurance or benefit plans where benefits are based olaparib following commencement of the otherwise of legal costs and or all or part on employees length of service and final first of several Phase III clinical programmes of any loss incurred or for which a provision salary typically averaged over one, three or for this asset.
We are satisfied that the has been established and we consider five years.
The UK and US defined benefit carrying values of our intangible assets recovery to be virtually certain, then the schemes were closed to new entrants in as at 31 December 2013 are fully justified best estimate of the amount expected 2000.
All new employees in these countries by estimated future cash flows.
The to be received is recognised as an asset.
are offered defined contribution schemes.
accounting for our intangible assets, Assessments as to whether or not to As detailed in the Group Accounting including details of our arrangements recognise provisions or assets and of the Policies section of the Financial Statements with Merck and our collaboration with amounts concerned usually involve a series from page 136, the Group adopted the BMS on Amylin products, is fully explained of complex judgements about future events amendments to IAS 19 Employee Benefits in Note 9 to the Financial Statements and can rely heavily on estimates and in 2013.
We continue to recognise all from page 150. assumptions.
AstraZeneca believes that actuarial gains and losses immediately Further details of the estimates and the provisions recorded are adequate through Other comprehensive income.
assumptions we make in impairment based on currently available information Investment decisions in respect of defined testing of intangible assets are included and that the insurance recoveries recorded benefit schemes are based on underlying in Note 9 to the Financial Statements.
However, given the actuarial and economic circumstances with inherent uncertainties involved in assessing the intention of ensuring that the schemes Litigation In the normal course of business, the outcomes of these cases and in have sufficient assets to meet liabilities as contingent liabilities may arise from estimating the amount of the potential they fall due, rather than meeting accounting product-specific and general legal losses and the associated insurance requirements.
The trustees follow a strategy proceedings, from guarantees or from recoveries, we could in future periods incur of awarding mandates to specialist, active environmental liabilities connected with our judgments or insurance settlements that investment managers, which results in a current or former sites.
Where we believe could have a material adverse effect on broad diversification of investment styles that potential liabilities have a less than 50% our results in any particular period.
The investment probability of crystallising, or where we are approach is intended to produce less The position could change over time, and unable to make a reasonable estimate of volatility in the plan asset returns.
there can, therefore, be no assurance that the liability, we treat them as contingent any losses that result from the outcome of In assessing the discount rate applied to liabilities.
These are not provided for but any legal proceedings will not exceed the the obligations, we have used rates on are disclosed in Note 25 to the Financial amount of the provisions that have been AA corporate bonds with durations Statements from page 176. booked in the accounts.
corresponding to the maturities of those obligations, except in Sweden where we have used rates on mortgage bonds as the market in high quality corporate bonds is insufficiently deep.
86 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information In all cases, the pension costs recorded Sarbanes-Oxley Act Section 404 Strategic Report in the Financial Statements are assessed in As a consequence of our NYSE listing, accordance with the advice of independent AstraZeneca is required to comply with The Strategic Report, which has been qualified actuaries, but require the exercise those provisions of the Sarbanes-Oxley Act prepared in accordance with the of significant judgement in relation to applicable to foreign issuers.
Section 404 requirements of the Companies Act 2006, assumptions for long-term price inflation of the Sarbanes-Oxley Act requires comprises the following sections: and, future salary and pension increases.
companies annually to assess and make AstraZeneca at a glance public statements about the quality and Further details of our accounting for Chairmans Statement effectiveness of their internal control over post-retirement benefit plans are included Chief Executive Officers Review financial reporting.
As regards Sarbanesin Note 18 to the Financial Statements Strategy Oxley Act Section 404, our approach is from page 159. Business Review based on the Committee of Sponsoring Therapy Area Review Taxation Organizations COSO 1992 framework.
Resources Review Accruals for tax contingencies require Our approach to the assessment has Financial Review management to make judgements and been to select key transaction and financial and has been approved and signed on estimates in relation to tax audit issues reporting processes in our largest operating behalf of the Board.
Amounts accrued are units and a number of specialist areas, based on managements interpretation A C N Kemp such as financial consolidation and of country-specific tax law and the Company Secretary reporting, treasury operations and taxation, likelihood of settlement.
Tax benefits are 6 February 2014 so that, in aggregate, we have covered a not recognised unless the tax positions significant proportion of each of the key line are probable of being sustained.
Once items in our Financial Statements.
Each of considered to be probable, management these operating units and specialist areas reviews each material tax benefit to assess has ensured that its relevant processes and whether a provision should be taken controls are documented to appropriate against full recognition of the benefit on standards, taking into account, in particular, the basis of potential settlement through the guidance provided by the SEC.
We negotiation and or litigation.
All such have also reviewed the structure and provisions are included in current liabilities.
operation of our entity level control Any recorded exposure to interest on tax environment.
This refers to the overarching liabilities is provided for in the tax charge.
control environment, including structure AstraZeneca faces a number of transfer of reviews, checks and balances that are pricing audits in jurisdictions around the essential to the management of a world and, in some cases, is in dispute with well-controlled business.
These disputes usually The Directors have concluded that our result in taxable profits being increased internal control over financial reporting is in one territory and correspondingly effective at 31 December 2013 and the decreased in another.
Our balance sheet assessment is set out in the Directors positions for these matters reflect Responsibilities for, and Report on, Internal appropriate corresponding relief in the Control over Financial Reporting on page territories affected.
KPMG Audit Plc has audited the Further details of the estimates and effectiveness of our internal control over assumptions we make in determining our financial reporting at 31 December 2013 recorded liability for transfer pricing audits and, as noted in the Auditors Reports and other tax contingencies are included in on the Financial Statements and on the Tax section of Note 25 to the Financial Internal Control over Financial Reporting Statements on page 183.
Sarbanes-Oxley Act Section 404 on page 128, their report is unqualified.
AstraZeneca Annual Report and Form 20-F Information 2013 87
